MedTrace Logo

Tecfidera and MRI for Brain Energy in MS

NCT02644083 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2018-08-29

No results posted yet for this study

Summary

The primary objective of this study is to test the hypothesis that DMF can improve mitochondrial function in the brain of people with MS. The investigators will assess mitochondrial function in the cerebral grey matter by measuring PCr and ATP by 31P magnetic resonance spectroscopy (MRS) and NAA in NAWM by 1H MRS.

Conditions

Interventions

DRUG

Dimethyl fumarate

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Rebecca Spain, MD, MSPH · Oregon Health and Science University

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02644083 on ClinicalTrials.gov